Alpa Nick, M.D., M.S.

Gynecologic oncology specialist. Passionate about women receiving individualized #GynOnc care within a welcoming environment.

[Alpa Nick, M.D., M.S. @AlpaNick]

@TimEdwards00 you in town? Would love to see you tonight at the CMHS reunion !

[Team Ovary, Memorial Sloan Kettering Cancer Center @TeamOvary_MSK]

Most uterine carcinosarcomas have detectable TROP2 expression. In an innovative study by @saramoufarrij1 and team, organoid models showed encouraging response to TROP2 targeted antibody drug conjugate sacituzumab govitecan. @TeamOvary_MSK @TeamEndo_MSK

https://t.co/iXnNuNrN3i

[Ovarcome @ovarcome]

This is Jana and Dr. @AlpaNick and their precious moment of Ovarcoming Together! 👏
See you all in your best PEARLS as we celebrate our Ovarcomers and Healthcare Heroes on May 17 with @shannonmiller96 as our Guest Extraordinaire! 👏
Keep inspiring, keep Ovarcoming! 🩵 #Ovare25

[Shannon Westin, MD, MPH, FASCO @ShannonWestin]

🙌Azenosertib (WEE1i) has high activity in CCNE1 positive recurrent #ovariancancer - 👏👏👏design trials based on the right science and you get great results!!!

Incredible durable response - 34.9% in IHC positive tumors!
@GOG #gyncsm #SGOMtg #SGO2025

[Shannon Westin, MD, MPH, FASCO @ShannonWestin]

🤩TROP2 ADC DB-1305 #Antibodydrugconjugate is very active in highly pretreated recurrent #ovariancancer!!
41% durable response rate
(7.3 mo DOR)
👏This agent is moving into phase 3 studies!!
#SGOMtg #SGO2025 #gyncsm

[erin medlin @meddles28]

🔥🔥🔥🔥TUBA-WISP II with amazing enrollment and the start of exciting and interesting data for high risk patients. Thank you Dr. Gootzen and the whole team! ⁦@SGO_org⁩ ⁦@GYNCancer⁩ #SGOMtg #SGO2025

[CancerNetwork® @CancerNetwrk]

The use of avutometinib plus defactinib exceeded the response threshold and will advance to stage 2, for patients with advanced or recurrent mesonephric or mesonephric-like gynecologic cancer. #gyncsm #SGO25 | @SGO_org

https://t.co/MtrX0Vs24F

[Shannon Westin, MD, MPH, FASCO @ShannonWestin]

Great question - @rne_md said it best - "🎶 Tell me Why?? 🎶". Does #immunotherapy provide better long term outcomes and adverse event profile compared to progesterone or surgery? #SGOMtg #SGO2025 #gyncsm

[Bhavana Pothuri @BPothuri]

Congratulations ⁦@JudeNawlo⁩ on ⁦evaluating post-EWOC practice patterns in elderly cohort #ovarinacancer pts! Pts w single agent carbo had worst outcomes- impt@to use platinum doublet when feasible. ⁦@SGO_org⁩ ⁦@GOG⁩ ⁦@IGCSociety⁩ @gyncsm ⁦

[Aiden Nick @Aiden_Nick9]

Had a great week in Biloxi, MS, the boys were able to go 3-1. Can’t wait for the rest of the season with this team!
Stats:
.500 (4-8) 2B, 3 RBI, 2 R, 2 SB, BB

1 2/3 innings 0H 0BB 0R 1K

@JulioBorbon20 @SBS_Athletics @PBRGowins @Texas_PG @PrepBaseball_TX @CoachCKirby2

[Shannon Westin, MD, MPH, FASCO @ShannonWestin]

Omitting full pelvic lymphadenectomy did not negatively impact survival in early stage #cervicalcancer

🤨Unclear why there was higher recurrence in the pelvic LND group vs pts that underwent sentinel lymph node biopsy #SGOMtg #gyncsm #SGO2025

[Shannon Westin, MD, MPH, FASCO @ShannonWestin]

Intriguing data for neoadjuvant #immunotherapy in resectable MMRd #endometrialcancer - high pathologic response rate but be careful of small n!!!

Looking forward to C93 (pembrolizumab) and Domenica (dostarlimab) study results in advanced and recurrent disease
#SGOMtg #gyncam

[Nicole D. Fleming MD @nicoleflemingmd]

Exciting Phase II data using Lenvatinib and Cadonilimab in adv/recur #endometrialcancer yielded 43% ORR and 93% disease control rate #SGOMtg #SGO2025

[Shannon Westin, MD, MPH, FASCO @ShannonWestin]

👀High detection rate of ctDNA at baseline in the DUO-E study of olaparib and duralumab in #endometrialcancer

🧐Exploratory analyses suggest biggest benefit to combo in ctDNA positive disease - need to prospectively study this group!

#SGOMtg #SGO2025 #gyncsm

[Nicole D. Fleming MD @nicoleflemingmd]

Expanded data on Keynote A18 @SGO_org from Dr Duska showed continued benefit of addition of Pembro to CRT in #cervicalcancer with improved PFS and OS and 33% reduction of death. #SGOMtg #SGO2025 @amandanfader

[Nicole D. Fleming MD @nicoleflemingmd]

Expanded results by Dr Moore from DUO-E evaluating biomarkers and ctDNA in MMR-proficient #endometrial cancer showing subgroups who may benefit from adding Olaparib to CP + Durvalumab. #SGOMtg #SGO2025 @ShannonWestin

[Alpa Nick, M.D., M.S. @AlpaNick]

@ovarcome 🩵🩵🩵🩵🩵🩵🩵

[Alpa Nick, M.D., M.S. @AlpaNick]

Opinion | Independent Surgeons Are Disappearing. Here's Why That Matters. https://t.co/IFkWjtgQ3H

[JAMA Oncology @JAMAOnc]

Most viewed in the last 7 days from @JAMAOnc:

In a study of over 4,500 cancer patients, those who quit smoking within 6 months of diagnosis through a cessation program showed the greatest survival benefit.

https://t.co/UKcoH8aQj7

[Ovarcome @ovarcome]

What a memorable and meaningful Book Launch event honoring our Ovarcomers and Caregivers, complete with reading and mingling. Thank you Dr. @AlpaNick for hosting and to all Physicians who attended to support their patients! 🙏 THIS is how #WeOvarcome! 🩵 #BookLaunch #Ovarcoming